Hope for Relapsed Leukemia: Can Ponatinib Bridge the Gap to Successful Transplants?
"A new study explores how ponatinib, a targeted therapy, can help patients with Philadelphia chromosome-positive leukemia reach potentially life-saving bone marrow transplants."
Outcomes for patients battling relapsed or refractory Philadelphia chromosome-positive (Ph+) leukemia have historically been bleak. However, the emergence of new treatments, including ponatinib, offers renewed hope. This third-generation tyrosine kinase inhibitor (TKI) demonstrates a potent effect against various mutations, including the challenging T315I mutation.
While ponatinib has shown promise in treating resistant chronic phase chronic myeloid leukemia (CP-CML), its effectiveness in advanced Ph+ leukemia requires innovative strategies. One such approach involves combining ponatinib with other therapies to facilitate a bridge to allogeneic hematopoietic cell transplantation (HCT), also known as a bone marrow transplant.
A recent single-center retrospective study sheds light on this approach, investigating the use of ponatinib as a salvage therapy to enable HCT in patients with relapsed or refractory Ph+ leukemia. The study highlights the potential of ponatinib to control the disease and create a path toward successful transplantation.
Ponatinib Responses and Safety
A 2024 report on ponatinib as frontline therapy for chronic-phase chronic myeloid leukemia (CML) describes high cytogenetic and molecular response rates in newly diagnosed patients. The same report cautions that frontline use is hindered by arterio- or vaso-occlusive events and other severe toxicities. A separate 2026 source notes that real-world data on ponatinib, particularly in Asian populations, remain limited.
Treatment Options and Unresolved Questions
For heavily pretreated CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), ponatinib demonstrated marked antileukemic efficacy and was approved based on the phase 2 PACE trial, according to a 2017 consensus article. Later-line CML remains difficult to treat: a 2023 review describes limited therapeutic options and poor response probability, and warns that sequential treatment is associated with reduced overall survival and may select mutations such as T315I. After allogeneic stem cell transplantation (Allo-SCT), a review identifies a lack of prospective randomized trials and unresolved questions about tolerability, optimal dose and duration, and whether maintenance should be prophylactic or pre-emptive.
The T315I Challenge and Ponatinib’s Development
A 2024 medicinal-chemistry review traces ponatinib’s development to the limitations of earlier CML treatments. It reports that first- and second-generation tyrosine kinase inhibitors—including imatinib, nilotinib, bosutinib, and dasatinib—are ineffective against ABL1 kinase-domain mutations, particularly T315I. Ponatinib, a third-generation inhibitor, was developed to address this treatment gap in CML and Ph+ ALL.
Ponatinib to the Rescue: Study Design and Patient Population
The study, conducted at a single center, retrospectively analyzed consecutive patients who received ponatinib as salvage therapy to facilitate allogeneic hematopoietic cell transplantation (HCT) for relapsed or refractory Ph-leukemia between January 2017 and July 2018.
- Mutation Detection: Mutation analysis revealed that eight patients had mutations in the tyrosine kinase domain, with seven exhibiting the T315I mutation.
- Ponatinib Dosage: The median dose of ponatinib administered was 15 mg, with a median treatment duration of 7 weeks (ranging from 4 to 23 weeks).
- Bridging to HCT: The median time from the start of ponatinib treatment to HCT was 54 days (ranging from 35 to 175 days).
Small Studies Report Responses After Relapse
In the real-life OPAL study of adults with relapsed or refractory Ph+ ALL treated with ponatinib-based therapy, the reported remission rate was 90%, and seven patients received allogeneic stem cell transplantation. A separate report on recurrent Ph+ central nervous system leukemia with the T315I mutation after Allo-HSCT says all patients achieved deep molecular response and CNS remission, at a median of 1.5 months after ponatinib treatment (range 0.7–3 months). In two reported cases of Ph+ ALL relapse after allogeneic transplantation, CAR-T therapy was followed by negative measurable residual disease maintained for 38 months without maintenance therapy.
Evidence Gaps and Treatment Toxicity
Ponatinib may be an alternative to allogeneic stem cell transplantation (allo-SCT) for patients with T315I-positive leukemia, but the cited comparison notes that no prospective trial has compared outcomes between T315I-positive patients treated with ponatinib and those who underwent allo-SCT. In a retrospective study of 78 ponatinib-treated CML patients at Moffitt Cancer Center from January 2011 through December 2017, thrombocytopenia was the most common non-CAE, occurring in 39.7% and in a dose-dependent fashion. These findings underscore that comparative evidence is lacking and treatment-related toxicity is a concern.
Four-Year Event-Free Survival in PONALFIL
Long-term results from the PONALFIL trial in adults with Ph+ ALL report a 4-year event-free survival probability of 66% (95% confidence interval, 45%–81%) when molecular relapse was counted as an event. The cited result provides a specific trial outcome under that definition; the available source material does not provide a comparison with ponatinib or transplant strategies.
A Promising Path Forward
This study offers a beacon of hope for patients with relapsed or refractory Ph+ leukemia. Salvage therapy with low-dose ponatinib appears to be a safe and effective strategy for controlling the disease and facilitating a bridge to potentially life-saving HCT. While further investigations are needed, these findings suggest that ponatinib can play a crucial role in improving outcomes for this challenging patient population. With continued research and refinement of treatment strategies, the future looks brighter for individuals battling Ph+ leukemia.
Balancing Response Potential Against Vascular Risk
In the PACE trial, an independent adjudication committee found an arterial occlusive event (AOE) rate of 17%, lower than the non-adjudicated rate of 25%. A 2024 safety analysis notes that ponatinib’s clinical benefits must be balanced against safety concerns, notably vascular events. Separately, a 2024 frontline CML report describes high molecular response rates but also reports arterio- or vaso-occlusive and other severe toxicities, reinforcing the need to weigh response potential against risk.